Fertility and Sterility
Volume 90, Issue 2 , Pages 378-384 , August 2008

Association of genetic variants of insulin degrading enzyme with metabolic features in women with polycystic ovary syndrome

  • Kehua Wang, M.D., Ph.D.

      Affiliations

    • Center for Reproductive Medicine, Shandong Provincial Hospital, Shandong University, Jinan, the People's Republic of China
    • Shandong Science and Technology Institute of Family Planning, Jinan, the People's Republic of China
    • ,
  • Li You, M.B.

      Affiliations

    • Center for Reproductive Medicine, Shandong Provincial Hospital, Shandong University, Jinan, the People's Republic of China
    • ,
  • Yuhua Shi, M.D., Ph.D.

      Affiliations

    • Center for Reproductive Medicine, Shandong Provincial Hospital, Shandong University, Jinan, the People's Republic of China
    • ,
  • Laicheng Wang, M.Sc.

      Affiliations

    • Central laboratory, Shandong Provincial Hospital, Shandong University, Jinan, the People's Republic of China
    • ,
  • Meixin Zhang, M.B.

      Affiliations

    • Shandong Science and Technology Institute of Family Planning, Jinan, the People's Republic of China
    • ,
  • Zi-Jiang Chen, M.D., Ph.D.

      Affiliations

    • Center for Reproductive Medicine, Shandong Provincial Hospital, Shandong University, Jinan, the People's Republic of China
    • Corresponding Author InformationReprint requests: Zi-Jiang Chen, M.D., Ph.D., Center for Reproductive Medicine, Shandong Provincial Hospital, Shandong University, 324 Jing-5-Wei-7 Road, Jinan 250021, China (FAX: 86-531-8706-8226).

Received 24 December 2006 ,Revised 6 June 2007 ,Accepted 6 June 2007.

References 

  1. Frank S. Polycystic ovary syndrome. N Engl J Med. 1995;333:853–861
  2. Yen SSC. Polycystic ovary syndrome (hyperandrogenic chronic anovulation). In:  Yen SCC,  Jaffe RB,  Barbieri RL editor. Reproductive endocrinology. Philadelphia: Saunders; 1999;p. 436–478
  3. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85:2434–2438
  4. Knochenhauer ES, Key TJ, Kashar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the Southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83:3078–3082
  5. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab. 1980;50:113–116
  6. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab. 1983;57:356–359
  7. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38:1165–1174
  8. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22:141–146
  9. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84:165–169
  10. Waterworth DM, Bennett ST, Gharani N, McCarthy MI, Hague S, Batty S, et al. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet. 1997;349:986–990
  11. Bennett ST, Todd JA, Waterworth DM, Franks S, McCarthy MI. Association of insulin gene VNTR polymorphism with polycystic ovary syndrome. Lancet. 1997;349:1771–1772
  12. Bennett ST, Todd JA. Human type 1 diabetes and the insulin gene: principles of mapping polygenes. Annu Rev Genet. 1996;30:343–370
  13. Huxtable SJ, Saker PJ, Haddad L, Walker M, Frayling TM, Levy JC, et al. Analysis of parent–offspring trios provides evidence for linkage and association between the insulin gene and type 2 diabetes mediated exclusively through paternally transmitted class III variable number tandem repeat alleles. Diabetes. 2000;49:126–130
  14. Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocrinol Rev. 1998;19:608–624
  15. Affholter JA, Cascieri MA, Bayne ML, Brange J, Casaretto M, Roth RA. Identification of residues in the insulin molecule important for binding to insulin-degrading enzyme. Biochemistry. 1990;29:7727–7733
  16. Meigs JB, Panhuysen CI, Myers RH, Wilson PW, Cupples LA. A genomewide scan for loci linked to plasma levels of glucose and HbA1c in a community-based sample of Caucasian pedigrees: the Framingham Offspring Study. Diabetes. 2002;51:833–840
  17. Wiltshire S, Hattersley AT, Hitman GA, Walker M, Levy JC, Sampson M. A genomewide scan for loci predisposing to type 2 diabetes in a U.K. population (the Diabetes UK Warren 2 Repository): analysis of 573 pedigrees provides independent replication of a susceptibility locus on chromosome 1q. Am J Hum Genet. 2001;69:553–569
  18. Ghosh S, Watanabe RM, Valle TT, Hauser ER, Magnuson VL, Langefeld CD, et al. The Finland–United States investigation of non-insulin-dependent diabetes mellitus genetics (FUSION) study. I. An autosomal genome scan for genes that predispose to type 2 diabetes. Am J Hum Genet. 2000;67:1174–1185
  19. Duggirala R, Blangero J, Almasy L, Dyer TD, Williams KL, Leach RJ, et al. Linkage of type 2 diabetes mellitus and of age at onset to a genetic location on chromosome 10q in Mexican Americans. Am J Hum Genet. 1999;64:1127–1140
  20. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A. 2003;100:4162–4167
  21. Fakhrai-Rad H, Nikoshkov A, Kamel A, Fernstrom M, Zierath JR, Norgren S, et al. Insulin-degrading enzyme identified as a candidate diabetes susceptibility gene in GK rats. Hum Mol Genet. 2000;9:2149–2158
  22. Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, et al. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol. 2004;164:1425–1434
  23. Groves CJ, Wiltshire S, Smedley D, Owen KR, Frayling TM, Walker M, et al. Association and haplotype analysis of the insulin-degrading enzyme (IDE) gene, a strong positional and biological candidate for type 2 diabetes susceptibility. Diabetes. 2003;52:1300–1305
  24. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25
  25. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005;15:97–98
  26. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrinol Rev. 1997;18:774–800
  27. San Millan JL, Corton M, Villuendas G, Sancho J, Peral B, Escobar Morreale HF. Association of polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab. 2004;89:2640–2646
  28. Meigs JB, Panhuysen CI, Myers RH, Wilson PW, Cupples LA. A genome-wide scan for loci linked to plasma levels of glucose and HbA(1c) in a community-based sample of Caucasian pedigrees: The Framingham Offspring Study. Diabetes. 2002;51:833–840
  29. Mulichak AM, Wilson JE, Padmanabhan K, Garavito RM. The structure of mammalian hexokinase-1. Nat Struct Biol. 1998;5:555–560
  30. Kim KY, Cho HS, Jung WH, Kim SS, Cheon HG. Phosphatase and tensin homolog deleted on chromosome 10 suppression is an important process in peroxisome proliferator-activated receptor-{gamma} signaling in adipocytes and myotubes. Mol Pharmacol. 2007;71:1554–1562
  31. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature. 2007;445:881–885
  32. Lehman DM, Hunt KJ, Leach RJ, Hamlington J, Arya R, Abboud HE, et al. Haplotypes of transcription factor 7-like 2 (TCF7L2) gene and its upstream region are associated with type 2 diabetes and age of onset in Mexican Americans. Diabetes. 2007;56:389–393
  33. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006;38:320–323
  34. Damcott CM, Pollin TI, Reinhart LJ, Ott SH, Shen H, Silver KD, et al. Polymorphisms in the transcription factor 7–like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance. Diabetes. 2006;55:2654–2659
  35. Gu HF, Efendic S, Nordman S, Ostenson CG, Brismar K, Brookes AJ, et al. Quantitative trait loci near the insulin-degrading enzyme (IDE) gene contribute to variation in plasma insulin levels. Diabetes. 2004;53:2137–2142
  36. Karamohamed S, Demissie S, Volcjak J, Liu C, Heard-Costa N, Liu J, et al. Polymorphisms in the insulin-degrading enzyme gene are associated with type 2 diabetes in men from the NHLBI Framingham Heart Study. Diabetes. 2003;52:1562–1567
  37. Florez JC, Wiltshire S, Agapakis CM, Burtt NP, de Bakker PI, Almgren PB, et al. High-density haplotype structure and association testing of the insulin-degrading enzyme (IDE) gene with type 2 diabetes in 4,206 people. Diabetes. 2006;55:128–135

 Supported by the National Basic Research Program of China (973 Program-2006CB944004) and the National High-Technology Research and Development Program of China (863 Program-2006AA02Z4A4).

PII: S0015-0282(07)01359-3

doi: 10.1016/j.fertnstert.2007.06.016

Fertility and Sterility
Volume 90, Issue 2 , Pages 378-384 , August 2008

Article Tools